TRex Bio, Inc. TRXB
IPO
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.49M | 2.49M | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.51M | 15.51M | |||
| Operating Income | -15.51M | -15.51M | |||
| Income Before Tax | -14.63M | -14.63M | |||
| Income Tax Expenses | 21.00K | 21.00K | |||
| Earnings from Continuing Operations | -14.65M | -14.65M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.65M | -14.65M | |||
| EBIT | -15.51M | -15.51M | |||
| EBITDA | -15.45M | -15.45M | |||
| EPS Basic | -3.11 | -3.11 | |||
| Normalized Basic EPS | -1.94 | -1.94 | |||
| EPS Diluted | -3.11 | -3.11 | |||
| Normalized Diluted EPS | -1.94 | -1.94 | |||
| Average Basic Shares Outstanding | 4.70M | 4.70M | |||
| Average Diluted Shares Outstanding | 4.70M | 4.70M | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||